Colossal Apr 2026

In October 2024, the company launched the Colossal Foundation , a non-profit dedicated to applying these technologies to today's endangered species. They are currently working on a vaccine for a deadly elephant virus (EEHV) and biobanking the "top 100" most imperiled species to ensure their genetic survival.

: Used to splice ancient DNA traits into modern genomes. Colossal

: The company aims to produce mammoth-like Asian elephant embryos by 2026, with the first calves expected by 2028. In October 2024, the company launched the Colossal

Rather than simple "cloning," Colossal uses a "de-extinction toolkit" to edit the DNA of a living relative to match an extinct ancestor. : The company aims to produce mammoth-like Asian

The story of most often refers to Colossal Biosciences , a Dallas-based biotechnology company founded in 2021 by entrepreneur Ben Lamm and Harvard geneticist George Church. Their mission is to "make extinction a thing of the past" by using advanced genetic engineering to bring back functional versions of extinct species and preserve those currently at risk. The Mission: De-Extinction and Preservation

: Partnering with the University of Melbourne, they have achieved over 99.9% accuracy in reconstructing the thylacine genome. The Technology "Toolkit"